DE69939720D1 - Fulvinsäure und deren Verwendung in der Behandlung von viralen Infektionen - Google Patents

Fulvinsäure und deren Verwendung in der Behandlung von viralen Infektionen

Info

Publication number
DE69939720D1
DE69939720D1 DE69939720T DE69939720T DE69939720D1 DE 69939720 D1 DE69939720 D1 DE 69939720D1 DE 69939720 T DE69939720 T DE 69939720T DE 69939720 T DE69939720 T DE 69939720T DE 69939720 D1 DE69939720 D1 DE 69939720D1
Authority
DE
Germany
Prior art keywords
viral infections
fulvic acid
treatment
condition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939720T
Other languages
English (en)
Inventor
Johannes Dekker
Constance Elizabeth Medlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfeinsmith Ltd
Original Assignee
Pfeinsmith Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfeinsmith Ltd filed Critical Pfeinsmith Ltd
Application granted granted Critical
Publication of DE69939720D1 publication Critical patent/DE69939720D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69939720T 1998-10-08 1999-10-08 Fulvinsäure und deren Verwendung in der Behandlung von viralen Infektionen Expired - Lifetime DE69939720D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA989190 1998-10-08
ZA992848 1999-04-21

Publications (1)

Publication Number Publication Date
DE69939720D1 true DE69939720D1 (de) 2008-11-20

Family

ID=27144980

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69932939T Expired - Lifetime DE69932939T2 (de) 1998-10-08 1999-10-08 Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
DE69939721T Expired - Lifetime DE69939721D1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren Verwendung in der Behandlung von Candida Infektionen
DE69939720T Expired - Lifetime DE69939720D1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren Verwendung in der Behandlung von viralen Infektionen
DE69939722T Expired - Lifetime DE69939722D1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren Verwendung in der Behandlung von Entzündungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69932939T Expired - Lifetime DE69932939T2 (de) 1998-10-08 1999-10-08 Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
DE69939721T Expired - Lifetime DE69939721D1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren Verwendung in der Behandlung von Candida Infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69939722T Expired - Lifetime DE69939722D1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren Verwendung in der Behandlung von Entzündungen

Country Status (7)

Country Link
US (1) US6569900B1 (de)
EP (4) EP1698333B1 (de)
JP (1) JP4700808B2 (de)
AT (4) ATE410159T1 (de)
AU (1) AU766198B2 (de)
DE (4) DE69932939T2 (de)
WO (1) WO2000019999A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7896944B2 (en) * 2004-06-23 2011-03-01 Lone Knight Limited Method for extracting fulvic acid molecules
WO2006064449A1 (en) * 2004-12-15 2006-06-22 Van Der Westhuizen Cornelis Fl Detoxifying and immunity-booster composition
US20080160111A1 (en) * 2005-02-28 2008-07-03 Hiroko Isoda Type I Allergy Inhibitor and Methods of Inhibiting the Onset of Type I Allergy Using Fulvic Acid
JP2006232785A (ja) * 2005-02-28 2006-09-07 Univ Of Tsukuba フルボ酸を用いるｉ型アレルギー抑制剤及びｉ型アレルギーの発症抑制方法。
US20070212434A1 (en) * 2006-03-07 2007-09-13 Day Kenneth S Compositions and methods for human use containing fulvic acid
US8114910B2 (en) 2006-05-02 2012-02-14 Pfeinsmith S.A. (Pty) Ltd. Acidic composition
BRPI0913586A8 (pt) * 2008-06-05 2018-03-13 Pfeinsmith Ltd combinação, e, uso de uma combinação.
DE102008058552A1 (de) 2008-11-21 2010-05-27 Mankau, Dieter, Prof. Dr. Federrahmen und Federkörper zur Abstützung z. B. einer Matratze
GB0900786D0 (en) 2009-01-19 2009-03-04 Natracine Uk Ltd Therapeutic compositions
GB0914966D0 (en) * 2009-08-27 2009-09-30 Natracine Uk Ltd Fulvic acid compositions and their use
WO2013023062A1 (en) * 2011-08-09 2013-02-14 Wilford Lynn C Antimicrobial agents and methods for use thereof in the abatement of food borne pathogenic organisms
WO2013132444A1 (en) 2012-03-07 2013-09-12 Natracine Uk Limited Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria
CN105246879A (zh) 2013-05-28 2016-01-13 英派尔科技开发有限公司 腐植酸衍生物以及制备的方法和用途
EP3004070B1 (de) 2013-05-28 2017-10-11 Empire Technology Development LLC Antioxidative huminsäurederivate sowie verfahren zur herstellung und verwendung
US10106570B2 (en) 2013-06-28 2018-10-23 Empire Technology Development Llc Edible plasticizers for food and food packaging films
WO2017102565A1 (en) * 2015-12-15 2017-06-22 Rita Dobmeyer Pharmaceutical composition comprising a fulvic acid and at least one boron-containing compound
US9820953B2 (en) * 2016-02-26 2017-11-21 Omni Bioceutical Innovations, Inc. Compositions of bioactive fulvate fractions and uses thereof
JP6120342B1 (ja) * 2016-03-08 2017-04-26 株式会社スタイルアンドバリュージャパン 美容組成物
US20220160649A1 (en) * 2019-03-20 2022-05-26 Rita DOBMEYER Pharmaceutical composition
EP3799854A1 (de) 2019-10-01 2021-04-07 Stefan Johannes Fellner Extrakt von organischen humifizierten materialien
KR102258006B1 (ko) * 2020-12-22 2021-05-28 허교 풀빅산을 유효성분으로 포함하는 항바이러스 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB244215A (en) 1924-10-09 1925-12-17 Richard William Bailey Improvements in or relating to gas or oil power plant
DE2850685A1 (de) * 1978-11-22 1980-06-04 Kneer Franz X Verfahren zur herstellung eines kolloiden schlammbades und schlammartiger pasten fuer die heilbehandlung
US5204368A (en) * 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
JPH0466508A (ja) * 1990-07-03 1992-03-02 Suntory Ltd 抗菌剤
JPH0687752A (ja) * 1992-09-04 1994-03-29 Kyowa Kagaku Kogyo Kk 抗菌水及びこの抗菌水の製造方法
CN1097990A (zh) * 1994-01-29 1995-02-01 康宏盛 一种治疗股癣的药物
JPH1017483A (ja) * 1996-06-26 1998-01-20 Keinzu Corp:Kk 皮膚疾患予防及び治療剤
TR199802702T2 (xx) * 1996-06-27 1999-05-21 Organoflo (Proprietary) Limited Bir s�v� verim artt�rma maddesinin yap�lmas� i�in bir y�ntem.
JPH119674A (ja) * 1997-06-25 1999-01-19 M S K Planning:Kk フミン酸を有効成分とする液体消臭剤と、その製造方法及びフミン酸を有効成分とした飲料用消臭剤と、その製造方法
CN1103339C (zh) * 1998-08-25 2003-03-19 祝亚勤 药用级泥炭黄腐植酸钠的制备方法

Also Published As

Publication number Publication date
EP1698333B1 (de) 2008-10-08
DE69939721D1 (de) 2008-11-20
DE69932939D1 (de) 2006-10-05
ATE410158T1 (de) 2008-10-15
DE69939722D1 (de) 2008-11-20
ATE410160T1 (de) 2008-10-15
DE69932939T2 (de) 2006-12-07
AU5992399A (en) 2000-04-26
AU766198B2 (en) 2003-10-09
US6569900B1 (en) 2003-05-27
ATE410159T1 (de) 2008-10-15
EP1700599B1 (de) 2008-10-08
JP4700808B2 (ja) 2011-06-15
EP1700600A1 (de) 2006-09-13
EP1698333A1 (de) 2006-09-06
ATE336997T1 (de) 2006-09-15
EP1700599A1 (de) 2006-09-13
EP1126837A1 (de) 2001-08-29
JP2002526407A (ja) 2002-08-20
EP1126837B1 (de) 2006-08-23
EP1700600B1 (de) 2008-10-08
WO2000019999A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
ATE410158T1 (de) Fulvinsäure und deren verwendung in der behandlung von viralen infektionen
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
ATE160561T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ATE185803T1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
ATE271896T1 (de) Salbe enthaltend mometason-furoat und salicylsäure zur topischen behandlung von psoriasis
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação
ATE193537T1 (de) Phosphorylierte derivate von verbindungen mit antiinflammatorischen oder analgetischer wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition